The pathophysiological mechanisms involved in fibrotic interstitial lung diseases (FILDs) are akin to those observed in idiopathic pulmonary fibrosis (IPF). implying the potential for shared therapeutic approaches. Pirfenidone exhibits antifibrotic and anti-inflammatory properties. making it the first small-molecule drug approved for treating IPF. https://ashleyshomestores.shop/product-category/7-piece-modular-sectional/